

Rec'd PCT/PTO 1 / DEC 2003

PCT/EP 03 / 50231

10/519060

Office européen
des brevets

2



Europäisches
Patentamt

European
Patent Office

REC'D 05 SEP 2003

WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02100720.8

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 02100720.8
Demande no:

Anmeldetag:
Date of filing: 18.06.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

F.R.I.D. R&D Benelux Sprl
Rue Descartes, 2
7000 Mons
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Hemodynamic luminal endoprosthesis

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61F2/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Hemodynamic luminal endoprosthesis

The invention concerns luminal endoprostheses to be placed in blood vessels, such as stents.

5

Background of the invention

Stents are generally placed within the lumen of a narrowed artery in cases when the outcome of angioplasty is uncertain, e.g. in the case of stenoses, recanalized occlusions or vessel dissection.

When a stent is unfolded, it applies a constant outward force on the vessel, maintaining the desired dimensions of the lumen and thus reducing the effects of stenosis.

However, recent studies on the subject revealed that placement of a luminal endoprosthesis can cause injuries to the artery wall, which leads to what is called intimal hyperplasia.

The vascular wall is composed of three layers, namely the intima (innermost layer composed of a single layer of endothelial cells), the media (middle layer which is composed of smooth muscle cells, elastic sheets, elastic fibrils network and bundles of collagenous fibers) and the adventitia (the outer layer).

It is now well established that intimal hyperplasia is the main process that induces belated narrowing of the lumen, even one or two years after intervention. It is related to the loss of endothelium and to medial injuries, which lead to an accelerated luminal smooth muscles proliferation migrating from the media or the intima and later to atherosclerosis degeneration.

Presently, studies to reduce what is called intimal hyperplasia (small muscle tissue proliferation which leads to restenosis) are aimed at anti proliferation or anti mitotic drugs that are fixed on the stent surface via a polymer matrix.

These methods suffer from several difficulties:

- the non uniformity of polymer surface and consequently the lack of consistency of the local drug delivery.
- the lack of consistency of the kinetic degradation of the polymer matrix.
- the stability of the polymer fixation on the surface of the stent.
- the determination of the right value of the drug dose to be affixed on the matrix.

The drugs used are similar to those which are used as anti cancer drugs, e.g. Taxol and Rapamycin. The use of high amounts of these molecules could be very harmful for the patient.

The restenosis of the stent induced by intimal hyperplasia poses a major problem for stent efficiency, mainly for arteries such as femorals , internal carotids or coronaries.

For the femoral artery, for example, many clinical trials show that stents give poor results due the restenosis which is a consequence of intimal hyperplasia. ; 50 to 60% failure.

A new approach showed that the restenosis was bound to unexpected mechanical problems.

30 Femoral artery:

A low shear stress along the cell wall is considered as an important factor of atherosclerotic plaque

formation. It has been correlated with intimal thickening and has been shown to alter endothelial cells structure and function.

- 5 The disturbed flow increases cell turnover particularly in the areas of low blood velocity, which could explain the loss of contact inhibition of cell growth.

Internal carotid:

- 10 The human carotid bifurcation is another example where flow model studies have demonstrated that the intimal plaques form in the low shear stress region of the carotid sinus opposite the flow and not in the high shear stress region along the inner wall of the carotid
15 artery.

Coronary artery

- 20 Similarly, the low shear stress is now shown to be a main cause of plaques formation at the branch points just distal to the bifurcation of the left main coronary artery into LAD and circumflex. This region exhibits a low blood flow velocity and a low shear stress, in other words the coronary artery tree demonstrates also a relationship between the shear stress and plaque
25 formation.

- The coronary arteries are subject to two systolic phases and one diastolic flow episode during each cardiac cycle, thus potentially placing them at a higher risk rank than systemic arteries to atherosclerosis. Shear
30 stress oscillation is directly influenced by heart rate. At higher rate, coronary arteries are exposed to more acute oscillatory low shear stress episodes, which accelerates the formation of atherosclerosis plaques. For

example, an increase in the mean heart rate from 70 to 80 beats/min would result in an increase of over 5 million heart beats per year. The duration of the systolic phase is generally constant for varying heart rates, whereas
 5 the duration of diastolic phase shortens with increasing heart rates.

It is important to mention that the effect of heart rate on atherosclerosis is associated with carotid artery atherosclerosis.

10 Summary of the invention

A higher flow velocity could suppress neointimal hyperplasia. However, this seems at first sight an absurdity, because it implies that, at constant flow rate, the section would have to be reduced. This led to
 15 the idea to design a stent in such a way that the flow velocity would remain globally the same, but would be increased along the cell wall, consequently improving the shear stress at wall level.

During the 12th conference of the European Society of
 20 Biomechanics (Dublin 2000) Nikos Stergiopolos demonstrated that avoiding intimal hyperplasia proliferation mainly in the case of low flow could be done by placing a streamlined cylindrical body in the centre of blood stream. The body deflects the central core of flow
 25 towards the wall, increasing the wall shear stress.

However, this brilliant theory could hardly be reduced to practice. The placing of a cylinder in the centre of the stream line of a diseased artery is not easy by itself, and it needs to be coupled with the prior
 30 placing of a standard stent, both to hold the atherosclerosis plaques and to anchor the cylinder. The inner cylinder further needs to be stable and firmly held in place.

The Applicant has developed a stent made out of a plurality of interlaced braided layers of metal filaments.

5 Prior experience in this field allowed him to develop a new type of stent which is braided in such a way that the making of a peripheral stent, a central, deflecting, cylinder and a linking between these two elements is achieved in a single shot.

10 The subject of the invention is a multilayer braided luminal self expanding stent for an anatomical conduit comprising a outer braided peripheral stent which is permanently linked to an inner braided hemodynamic flow deflector by at least two filaments that make part
15 of the common braided structure.

The multilayer technology seems to be the right solution because it is possible to have in one shot both cylinders made and simultaneously linked together.

20 In other words, a multilayer machine which is able to braid six layers in one shot could be used to braid the first two layers together around a mandrill with the full number of wires needed.

The second and the third layers will handle only four or eight carriers with filled wires in order to
25 connect the first two layers to the last two ones.

The result is a self expanding stent as described above.

The gap variation between the two commonly braided structures is broadly between 10 to 90% of the nominal
30 diameter of the outer stent. The two cylindrical structures are linked together by this multilayer technique in such a way that they form one single body.

The advantage of this design is that, when put in place, it increases the velocity of the blood along the inner wall of the vessel and thereby the shear stress. An increase of shear stress of the blood elongates endothelial cells in the direction of the flow. The cells also align themselves in the direction of the flow, and the shape of a confluent layer of endothelial cells changes from polygonal to ellipsoid when exposed to unidirectional shear. Endothelial cells produce nitric oxide, which is an important element for maintaining the vasodilator or vasorelaxing tonus in blood vessels. Nitric oxide inhibits platelet aggregation and adhesion, and modulates leukocyte adhesion and migration. In other words inducing the production of nitric oxide prevents stent restenosis by eliminating intimal hyperplasia thickening.

Brief description of the figures

Other particulars and advantages of the invention will become apparent from the description hereinafter of some particular embodiments of the invention, reference being made to the appended drawings in which:

Fig. 1 is a sketch of the aspect of the blood flow, with and without the inner core of a stent according to the invention.

Fig. 2 is a sketch of a sectional view along the axis of the stent.

Fig. 3 is a sketch of a sectional view normal to the axis of the stent

Detailed description of the figures

Fig. 1 shows a diagrammatical view of the velocity profile of a flow of blood, with (right side of the Fig.) or without (left side of the Fig.) the hemodynamic deflecting core 2 of the stent of the invention 4.

5 In the absence of core 2, the velocity cube 6a is classical : the velocity decreases progressively from a maximum to zero at the very contact of the wall 8, allowing the anarchic growth of wall cells that in time will impede the even passage of blood.

10 Turning now to the left side of the figure, one can see that the blood, deflected from the centre of the vessel by the hemodynamic core 2, induces a steeper flow profile 6b near the wall 8. The shear stress thus improved drags along the molecules that would induce a
15 reaction of the wall cells.

Fig. 2 and 3 display the general structure of the stent 4, that exhibits a central hollow braided hemodynamic core 2 and a "classical" peripheral stent structure 10, the core and the peripheral structures
20 being linked by wires 12 belonging to both braids.

To obtain this kind of structure, at least one or two wires are braided in helix simultaneously with the inner and the outer layers of braiding.

To control the empty space between the two
25 cylindrical structures, the easiest way is to fill the intermediate spindles with filaments of a material that is able to be dissolved (e.g. in hot water) after the braiding process, thus leaving a corresponding empty space in the braiding.

Example :

A braiding machine is equipped with spindles so as to be able to realise a multilayer braid made out of 24 or 48 wires, according to the nominal size of the stent.

- 5 The spindles corresponding to the first two layers are loaded with metal wires. The spindles corresponding to the 3rd layer are loaded with PVA (polyvinylalcohol) filament (Kuralon® or Solveon®), but for two to five of them (according to the final size of the stent), that are
- 10 loaded in a symmetrical way (thus in a diametrically opposed position), by metal wires. These metal wires which make the junction with the last two layers, are made out, as the first and second one, of metal.

- 15 When the braiding is finished, the braid is extracted from the mandrel on which it has been braided. It is then put in hot water (between 50 and 70°C) so as to dissolve the PVA filaments, thus freeing the space between the two distinct inner and outer structures.

- 20 The thickness of the PVA filament can be varied according to the width to be preserved between the peripheral stent and the inner core 2. The dimensions of the hollow inner core 2 itself are sufficient to modify the hemodynamic conditions of the blood flow, as described above.

- 25 In vitro experiments showed that the shear stress must reach a value of 15 dyne/cm² to affect the growth of endothelial cells. Below this value, the shear stress induce the formation of plaque and an anarchic growth of muscular cells. Below 2 dyne/cm², the neointimal
- 30 formation increases sharply, provoking rapid lesions.

The framework of the present stent can be made out of nickel titanium alloy or in cobalt alloy as Elgiloy or Phynox, or in stainless steel.

The metal wires can be submitted to a thermal treatment so as to reach a rigidity sufficient to withstand the crushing.

5 A further advantage of the present structure is that it reacts as a single element, capable of being squeezed and to elongate exactly as a classical stent. The structure is also very light, it can be reduced to a minute diameter, allowing an easy placement and a very good flexibility. It is further possible to use classical
10 applicators to put it in place in a single operation.

CLAIMS

5

1. A multilayer braided luminal self expanding stent (4) for an anatomical conduit (8) comprising a outer braided peripheral stent (10) which is permanently linked to an inner, braided, hemodynamic flow deflector
10 (2) by at least a pair of filaments (12) that make part of the common braided structure.

2. A multilayer stent according to claim 1 characterised in that the outer structure (10) comprises a first and a second layers which are connected by at least
15 a pair of filled wires (12) in order to connect the first two layers to the deflector, the latter comprising last two layers.

3. A multilayer stent according to claim either one of claims 1 and 2 characterised in that the gap between
20 the two commonly braided structures is between 10 to 90% of the nominal diameter of the outer stent (10) .

ABSTRACT

5

A multilayer braided luminal self expanding stent (4) for an anatomical conduit (8) comprising a outer braided peripheral stent (10) which is permanently linked to an inner, braided, hemodynamic flow deflector (2) by
10 at least a pair of filaments (12) that make part of a common braided structure.

Fig. 1

15

20

Fig 1




Fig 2




Fig 3

